摘要
目的观察合并轻度低蛋白血症小细胞肺癌(SCLC)患者,应用依托泊苷联合顺铂(EP)化疗后不良反应发生情况,并评价其安全性。方法将72例SCLC患者根据化疗前白蛋白水平分为观察组(白蛋白水平为30~40 g·L^-1)和对照组(白蛋白水平为40~55 g·L^-1),2组均给予EP方案化疗。比较2组患者单次化疗后的药物不良反应发生情况。结果观察组和对照组患者不良反应类别基本相同,常见的有胃肠功能紊乱及骨髓抑制,其中Ⅲ级药物不良反应主要表现为过敏反应、剧烈呕吐、严重腹泻和骨髓抑制。观察组Ⅲ级药物不良反应总发生率显著高于对照组(30.95%vs 10.00%,P<0.05);Ⅳ级骨髓抑制发生率也显著高于对照组(28.57%vs 6.67%,P<0.05)。除骨髓抑制外,2组患者均未出现其他Ⅳ级药物严重不良反应。结论合并轻度低蛋白血症患者化疗后Ⅲ~Ⅳ级严重药物不良反应发生率明显增加,尤其是存在严重的骨髓抑制。因此,该类患者化疗时应引起临床医师足够的重视,建议及时纠正血浆白蛋白水平并合理调整化疗方案。
AIM To evaluate the safety of etoposide plus cisplatin(EP)regimen in the treatment of patients with small cell lung cancer(SCLC)complicated with hypoalbuminemia.METHODS A total of 72 patients with SCLC were divided into treatment group(albumin level 30-40 g·L^-1)and control group(albumin level 40-55 g·L^-1)respectively.The 2 groups were given EP regimen chemotherapy.The occurrence of adverse drug reactions(ADRs)in 2 groups after once cycle of chemotherapy were compared.RESULTS The 2 groups had the same types of ADRs,and the most common were gastrointestinal dysfunction and myelosuppression.The ADRs of gradeⅢmainly included allergic reactions,severe vomiting and diarrhea and myelosuppression.The ADRs of the observation group were significantly higher than those of the control group.The difference between 2 groups(30.95%vs 10.00%)was statistically significant(P<0.05).Except for myelosuppression,there were no other ADRs of gradeⅣhappened in 2 groups.The difference between 2 groups in the incidence of gradeⅣmyelosu-ppression in treatment group(28.57%)and control group(6.67%)was significant(P<0.05).CONCLUSION Patients with hypoalbuminemia have a significant increase in serious ADRs of gradeⅢ-Ⅳafter chemotherapy,especially in the presence of severe myelosuppression.Therefore,it should be given enough attention by clinicians.It is recommended to correct plasma albumin levels in a timely manner and rationally adjust the chemotherapy regimen.
作者
于思源
冯志平
冯淑娴
YU Siyuan;FENG Zhiping;FENG Shuxian(Department of Pharmacy,Jiangmen Central Hospital,Affiliated Jiangmen Hospital of Sun Yat-Sen.University,Jiangmen 529000,China)
出处
《中国临床药学杂志》
CAS
2020年第3期190-193,共4页
Chinese Journal of Clinical Pharmacy
